Inhibiting PD-L1 palmitoylation via 2-BP or silencing of DHHC3 greatly reduces the expression of PD-L1 in tumor cells and therefore promotes T cell-mediated antitumor immunity (Yao et al., 2019). This evidence concerns the gene CD274 and neoplasm.